Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients With Chronic Widespread Musculoskeletal Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome (Disorder)

This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.

Study Overview

• Status: Terminated
• Conditions: Mast Cell Activation Syndrome; Mast Cell Activation Disorder Idiopathic
• Intervention / Treatment: Drug: FSD201; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada
      • Toronto Rehabilitation Institute
• United States
  • Missouri
    • Weldon Spring, Missouri, United States, 63304
      • Saint Charles Clinical Research
  • New York
    • New York, New York, United States, 10016
      • Norman Marcus Pain Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• Clinical diagnosis of idiopathic MCAS as per the global consensus diagnostic criteria
• Adults with widespread chronic pain (in three or more body regions);
• Chronic pains of intensity greater than or equal to 4.0 but less than or equal to 9.0 on a Numeric Pain Rating Scale, symptom duration of more than 6 months;
• Subject agrees to use only acetaminophen (up to 1000 mg per dose and not to exceed 3000 mg/day) or diphenhydramine (up to 300 mg/day) as rescue medication for chronic widespread musculoskeletal nociplastic pains throughout the trial;
• The subject is willing to maintain current activity and exercise levels throughout the study;
• During the study, the subject agrees not to initiate or change any non-pharmacologic interventions (including chiropractic care, physical therapy, psychotherapy, and massage therapy). Any ongoing non-pharmacologic intervention must be stable for at least 4 weeks before screening and should be continued for the duration of the study;

Key Exclusion Criteria:

• The subject has pain that cannot be clearly differentiated from or that could interfere with the assessment of chronic musculoskeletal nociplastic pain secondary likely to idiopathic MCAS (post-herpetic neuralgia, traumatic injury, prior surgery, complex regional pain syndrome);
• Adults with chronic cancer pain;
• Adults with inflammatory connective tissue disorder or rheumatological disorder-related pain, for example rheumatoid arthritis;
• Adults with focal musculoskeletal pain;
• Adults with skin diseases (chronic urticaria, pemphigus, lupus, rosacea etc.);
• Adults with endocrinological disorders (acute hypothyroidism, acute adrenal insufficiency etc.);
• Adults with systemic gastrointestinal conditions (Inflammatory bowel disorders);
• Significant psychological comorbidities: PHQ-9 score greater than 20; and GAD-7 score greater than 15 (indication of severe anxiety that could interfere with accurate logging of pain ratings);
• Current or recent (within 12 months of screening) history of a substance use disorder including cannabinoid or alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5);
• Subject has neurologic disorder unrelated to chronic widespread musculoskeletal nociplastic pains (phantom limb from amputation, vitamin B12 deficiency, chronic inflammatory demyelinating polyneuropathy), circulatory disorder (peripheral artery disease), a skin condition in the area of neuropathy that could alter sensation (plantar ulcer), or other painful conditions (arthritis) that could interfere with reporting of pain due to chronic widespread musculoskeletal nociplastic pains;
• Current severe or uncontrolled major depressive disorder or anxiety disorders. Mild to moderate major depression or anxiety disorders are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study. Stable doses of SSRIs are allowed for the treatment of depression if the dose is stable for 60 days before Screening Visit;
• Subject has a history of suicide attempt or suicidal behaviour within the last 12 months or has suicidal ideation within the previous 12 months or who is at significant risk to commit suicide, as judged by the Investigator at Screening and/or Randomization Visit;
• Patients with active malignancy or history of malignancy, except for basal cell or squamous cell carcinoma and actinic keratosis. Basal cell carcinoma and small squamous cell carcinoma of the skin which have been excised according to guidelines within the last 5 years or in situ cervical carcinoma that has been fully treated and shows no evidence of recurrence are allowed;
• Individuals with generalized joint hypermobility secondary to hereditary connective tissue disorders like Ehlers Danlos Syndrome;
• Individuals with high baseline serum tryptase levels suggestive of Primary or Secondary MCAS (defined as above the normal range of 2.2 to 13.2 µg/L).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FSD201; Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally from Day 0 to Day 56.	Drug: FSD201; Tablets for oral administration.
Placebo Comparator: Placebo; Participants will receive placebo matched to 600 mg FSD201 tablets twice daily (BID) orally from Day 0 to Day 56.	Drug: Placebo; Placebo tablets matched to FSD201 for oral administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain Intensity	Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity score measured by an 11-point numerical pain rating scale (NPRS). NPRS is an 11-point scale from 0 to10 where the higher number indicates worse pain. Averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28	Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of subjects achieving ≥30% reduction in Numerical Pain Rating Scale (NPRS) score at the end of treatment with FSD201 at the end of treatment with FSD201	Change from baseline in the weekly average of the average daily pain intensity measured by Numerical Pain Rating Scale (NPRS). NPRS is an 11-point scale from 0 to 10 where the higher number indicates worse pain. NPRS averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28 Day 56: calculated weekly average from Day 49 to Day 55 for the NPRS.	Day 28, Day 56
Change in Patient Global Impression of Change (PGIC)	Change in Patient Global Impression of Change (PGIC) after 56 days treatment from 1 to 7 where the higher number indicates a larger improvement.	Day 56
Change or reduction in patient average daily NPRS	Change or reduction in patient average daily Numerical Pain Rating Scale (NPRS) after 56 days treatment. NPRS is an 11-point scale from 0 to 10 where the higher number indicates worse pain. NPRS averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 56: calculated weekly average from Day 49 to Day 55 for the NPRS	Day 56
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance- Short Form (SF) 8a	Change from baseline (Day 0) in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form (SF) 8a after 56 days treatment. PROMIS sleep disturbance is a series of 8 questions, each on a 5-point scale (1-5) where the higher number indicates a worse outcome. A total score out of 40 will be calculated.	Day 56
Change in the PROMIS Pain Interference- SF 8a score	Change from baseline (Day 0) in the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference - SF 8a score after 56 days treatment. PROMIS pain interference is a series of 8 questions, each on a 5-point scale (1-5) where the higher number indicates a worse outcome. A total score out of 40 will be calculated.	Day 56
Change in the PROMIS General Life Satisfaction- SF 5a	Change from baseline (Day 0) in the Patient-Reported Outcomes Measurement Information System (PROMIS) General Life Satisfaction - SF 5a after 56 days treatment. PROMIS General Life Satisfaction is series of 5 questions, each on a 7-point scale (1-7) where the higher number indicates a better outcome. A total score out of 35 will be calculated.	Day 56
Change in the PROMIS Fatigue- SF 8a	Change from Baseline (Day 0) in the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue - SF 8a after 56 days treatment. PROMIS Fatigue is a series of 8 questions, each on a 5-point scale (1-5) where the higher number indicates a worse outcome. A total score out of 40 will be calculated.	Day 56
Reduction of plasma serum mast cell tryptase, IL-6, and IL-1beta during FSD201 treatment	Determine whether FSD201 treatment reduces serum mast cell tryptase, IL6, and IL-1beta during treatment compared to Day 0	Day 14, Day 28 and Day 56
Percentage of subjects achieving ≥30% reduction in NPRS score	Percentage of subjects achieving ≥30% reduction in Numerical Pain Rating Scale (NPRS) score. NPRS is an 11-point scale from 0 to10 where the higher number indicates worse pain. NPRS averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28 Day 56: calculated weekly average from Day 49 to Day 55 for the NPRS	Day 28, Day 56
Change in Daily Sleep Interference Scale (DSIS)	Daily Sleep Interference Scale (DSIS) is an 11-point scale (0-10 where the higher number indicates worse ability to sleep. Averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28 Day 56: calculated weekly average from Day 50 to Day 56 for the DSIS	Day 28, Day 56
Change in Patient Global Impression of Change (PGIC)	Change in Patient Global Impression of Change (PGIC) from 1 to 7 where the higher number indicates a larger improvement.	Day 28, Day 56
Change in pain intensity on the NPRS from baseline to each week of treatment	Change in pain intensity on the Numerical Pain Rating Scale (NPRS) score from baseline to each week of treatment. NPRS is an 11-point scale from 0 to 10 where the higher number indicates worse pain. Averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1; Week 1: calculated weekly average from Day 0 to Day 6; Week 2: calculated weekly average from Day 7 to Day 13; Week 3: calculated weekly average from Day 14 to Day 20; Week 4: weekly average from Day 21 to Day 27; Week 5: calculated weekly average from Day 28 to Day 34; Week 6: calculated weekly average from Day 35 to Day 41; Week 7: calculated weekly average from Day 42 to Day 48; Week 8: calculated weekly average from Day 49 to Day 55	Day 0 to Day 56
Percentage of subjects achieving ≥50% reduction in NPRS	Change from baseline in the weekly average of the average daily pain intensity measured by Numerical Pain Rating Scale (NPRS) score from baseline to each week of treatment. NPRS is an 11-point scale from 0 to 10 where the higher number indicates worse pain. Baseline: calculated weekly average from Day -7 to Day -1 Day 56: calculated weekly average from Day 49 to Day 55	Week 1 to Week 8
Total amount of rescue medication used	Total amount of rescue medication used	Day 0 to Day 56
Incidence and severity of treatment-emergent adverse events (TEAEs)	Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the dosing period	Day 0 to Day 56
Incidence and severity of treatment-emergent changes in laboratory values	Incidence and severity of treatment-emergent changes in laboratory values at Day 56	Day 56
Change from baseline in sitting blood pressure at each in-patient visit	Change from baseline (Day 0) in sitting blood pressure at each in-patient visit	Day 14, Day 28, Day 56
Change from baseline in heart rate at each in-patient visit	Change from baseline (Day 0) in heart rate at each in-patient visit	Day 14, Day 28, Day 56
Change from baseline in body temperature at each in-patient visit	Change from baseline (Day 0) in body temperature at each in-patient visit	Day 14, Day 28, Day 56
Change from baseline in oxygen saturation at each in-patient visit	Change from baseline (Day 0) in oxygen saturation using Pulse oximetry at each in-patient visit	Day 14, Day 28, Day 56
Change from baseline in breathing rate at each in-patient visit	Change from baseline (Day 0) in breathing rate at each in-patient visit	Day 14, Day 28, Day 56

Collaborators and Investigators

• Sponsor: Quantum Biopharma
• Investigators: Study Director: Andrzej Chruscinski, MD, FSD Pharma

Study record dates

Study Major Dates

• Study Start (Actual): January 19, 2023
• Primary Completion (Actual): May 24, 2023
• Study Completion (Actual): May 24, 2023

Study Registration Dates

• First Submitted: November 23, 2022
• First Submitted That Met QC Criteria: December 8, 2022
• First Posted (Actual): December 15, 2022

Study Record Updates

• Last Update Posted (Actual): April 21, 2026
• Last Update Submitted That Met QC Criteria: March 31, 2026
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mast Cell Activation Disorders; Immune System Diseases; Mast Cell Activation Syndrome
• Other Study ID Numbers: FSD201-010

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No